|
|
News Breaks | | | | February 12, 2013 | | 07:17 EDT |  | CYCC | Cyclacel receives U.S., EU patents for sapacitabine used with HDAC inhibitors
Cyclacel Pharmaceuticals announced the issuance of U.S. Patent No. U.S. 8,349,792 and European Patent No 2,101,790. Both patents include claims to combination treatment of sapacitabine, the Company's lead product candidate, with histone deacetylase, or HDAC, inhibitors. The patents provide exclusivity until June 2029 and December 2027 respectively. | |
|
News For CYCC From The Last 14 Days Check below for free stories on CYCC the last two weeks. |
|
|
| May 16, 2013 | | 10:00 EDT |  | CYCC | Cyclacel Pharmaceuticals falls 10.1%
Cyclacel Pharmaceuticals is down 10.1%, or 35c, to $3.12 | | | 09:03 EDT |  | CYCC | Cyclacel Pharmaceuticals 6.667M share Spot Secondary priced at $3.00
 Subscribe for More Information | | | May 15, 2013 | | 16:02 EDT | | CYCC | Cyclacel Pharmaceuticals files to sell common stock, no amount given
Subscribe for More Information | |
|
|
|
|
|
|
